文献速递头颈部肿瘤放疗

剂量递增大分割自适应放疗联合阿替利珠单抗治疗晚期头颈癌的1期试验

A Phase 1 Trial of Dose-Escalated Hypofractionated Adaptive Radiation Therapy With Atezolizumab for Advanced Head and Neck Cancers.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-07-17

该单中心1期试验纳入18例晚期头颈鳞癌患者,评估大分割自适应放疗(15次)剂量递增至50、55或60 Gy联合阿替利珠单抗的最大耐受剂量。初期5例同步阿替利珠单抗者中3例出现HSV-1再激活及过度毒性,方案修订为放疗后序贯阿替利珠单抗;修订后未见剂量限制性毒性,放疗最大耐受剂量为60 Gy,60 Gy组7例无局部区域失败,1年无进展生存率71.4%。

要点

  • 同步阿替利珠单抗联合大分割放疗可致HSV-1再激活等过度毒性。
  • 修订为放疗后序贯阿替利珠单抗后,放疗最大耐受剂量为60 Gy/15次。
  • 60 Gy组7例无局部区域失败,1年无进展生存率71.4%。

核心结论

  • 大分割自适应放疗剂量可安全递增至60 Gy/15次联合辅助阿替利珠单抗,未见新的安全性信号。
  • 同步阿替利珠单抗联合大分割放疗以此前未报告的方式促进HSV-1再激活,导致过度剂量限制性毒性。

研究设计与样本

  • 单中心1期试验,采用时间-事件持续再评估方法进行放疗剂量递增。
  • 纳入18例年龄≥18岁的晚期头颈鳞癌患者(11男7女,中位年龄74岁,范围52-89岁)。
  • 放疗15次,总剂量递增至50、55或60 Gy针对大体肿瘤;阿替利珠单抗1680 mg每4周一次,治疗后最多1年。
  • 主要终点为确定放疗的最大耐受剂量。

主要发现

  • 初始5例在放疗第1天接受阿替利珠单抗(50 Gy/15次),其中3例出现HSV-1再激活伴过度毒性。
  • 放疗最大耐受剂量为60 Gy。
  • 接受60 Gy治疗的7例患者中未见局部区域失败,1年无进展生存率为71.4%。

关键数值与推荐

  • eligible患者为初诊转移性HNSCC或局部T3-T4 N0-N3、T0-T4 N1-N3 HNSCC,且符合以下之一:不适合同步顺铂(参照NRG HN-004资格)、拒绝同步顺铂放化疗、不可切除口腔癌、或根治性手术后单纯复发。
  • 放疗剂量水平1为50 Gy/15次,递增至55 Gy或60 Gy。
  • 阿替利珠单抗剂量为1680 mg,每4周一次,治疗后最多1年。

临床怎么用

  • 晚期头颈鳞癌患者可考虑大分割自适应放疗递增至60 Gy/15次联合辅助阿替利珠单抗。
  • 避免同步阿替利珠单抗与大分割放疗,以降低HSV-1再激活风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the maximum-tolerated dose (MTD) of dose-escalated hypofractionated adaptive radiation therapy with atezolizumab in patients with head and neck squamous cell carcinomas (HNSCCs) in a phase 1 trial. METHODS AND MATERIALS: Dose-escalated hypofractionated adaptive radiation therapy was a single-center phase 1 trial. Eligible patients were aged ≥18 years with de novo metastatic HNSCC or localized American Joint Committee on Cancer 8th edition T3-T4 N0-N3, T0-T4 N1-N3 HNSCC meeting one of the following criteria: (1) not candidates for concurrent cisplatin mirroring eligibility for NRG HN-004; (2) refused concurrent cisplatin-based chemoradiation; (3) had unresectable oral cavity cancer; or (4) had recurrent disease after definitive surgical resection alone. Patients received 15 fractions of radiation to escalating total doses of 50, 55, or 60 Gy to gross disease based on a time-to-event continual reassessment methodology. Atezolizumab (1680 mg) was delivered every 4 weeks for up to 1 year after treatment. The primary endpoint of the study was to determine the MTD of radiation. RESULTS: Eighteen patients were enrolled (11 men and 7 women, median age of 74 years [range, 52-89 years]). Five patients were enrolled in radiation dose level 1 (50 Gy in 15 fractions) and received atezolizumab on the first day of radiation. Three of these patients developed Herpes Simplex Virus Type 1 reactivation with excess toxicity. As such, the study was amended to remove the concurrent atezolizumab dose. Thirteen additional patients enrolled and began receiving atezolizumab after radiation. No dose-limiting toxicities were seen after the amendment, and the MTD of radiation was 60 Gy. No loco-regional failures were seen among 7 patients treated to 60 Gy with a 1-year progression-free survival of 71.4%. CONCLUSIONS: Radiation dose may be safely escalated to 60 Gy in 15 fractions with adjuvant atezolizumab with no new safety signals. However, concurrent atezolizumab with hypofractionated radiation promoted Herpes Simplex Virus Type 1 reactivation in a previously unreported manner, resulting in excess dose-limiting toxicities.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Awan M, Tarima S, Zenga J, et al. A Phase 1 Trial of Dose-Escalated Hypofractionated Adaptive Radiation Therapy With Atezolizumab for Advanced Head and Neck Cancers. Int J Radiat Oncol Biol Phys. 2026. PMID: 42467032. doi:10.1016/j.ijrobp.2026.06.3053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。